Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Akoya Biosciences, Inc. AKYA NASDAQ

NASDAQ Global Select • Healthcare • Medical - Instruments & Supplies • US • USD

SharesGrow Score
41/100
1/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$2.40
+86%

Akoya Biosciences, Inc. (AKYA) is a Medical - Instruments & Supplies company in the Healthcare sector, currently trading at $1.29. It has a SharesGrow Score of 41/100, indicating a mixed investment profile with 1 out of 7 criteria passed.

Analyst consensus target is AKYA = $2 (+86% upside).

Financials: revenue is $82M, +16.6%/yr average growth. Net income is $55M (loss), growing at -13.9%/yr. Net profit margin is -67.8% (negative). Gross margin is 58.6% (-3.7 pp trend).

Balance sheet: total debt is $84M against $8M equity (Debt-to-Equity (D/E) ratio 11.08, leveraged). Current ratio is 2.61 (strong liquidity). Debt-to-assets is 67.3%. Total assets: $125M.

Analyst outlook: 2 / 9 analysts rate AKYA as buy (22%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 48/100 (Partial), Past 0/100 (Fail), Health 33/100 (Fail), Moat 41/100 (Fail), Future 52/100 (Partial), Income 10/100 (Fail).

$2.40
▲ 86.05% Upside
Average Price Target
The 12-month price target for Akoya Biosciences, Inc. is $2.40.

AKYA SharesGrow Score Overview

47/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 48/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 33/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 41/100
Gross margin is + market cap
FUTURE 52/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — AKYA

✓
VALUE Pass
100/100
AKYA trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $2, implying +55% from the current price $1. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
48/100
AKYA: +16.6%/yr revenue is, -13.9%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✗
HEALTH Fail
33/100
Balance sheet AKYA: Debt-to-Equity (D/E) ratio 11.08 (leveraged), Current ratio is 2.61 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
41/100
AKYA: Gross margin is 58.6% (-3.7 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 41/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
52/100
Analyst outlook: 2 / 9 analysts rate AKYA as buy (22%). Analyst consensus target is $2 (+55% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
AKYA: Net profit margin is -67.8%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.931-3.42
Volume715.25K
Avg Volume (30D)582.12K
Market Cap$64.44M
Beta (1Y)1.35
Share Statistics
EPS (TTM)-1.12
Shares Outstanding$49.42M
IPO Date2021-04-16
Employees205
CEOBrian McKelligon
Financial Highlights & Ratios
Revenue (TTM)$81.67M
Gross Profit$47.88M
EBITDA$-37.14M
Net Income$-55.37M
Operating Income$-46.73M
Total Cash$35.04M
Total Debt$84.15M
Net Debt$72.37M
Total Assets$125.01M
Price / Earnings (P/E)-1.2
Price / Sales (P/S)0.79
Analyst Forecast
1Y Price Target$2.40
Target High$2.40
Target Low$2.40
Upside+86.0%
Rating ConsensusHold
Analysts Covering9
Buy 22% Hold 78% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS00974H1041

Price Chart

Track all markets on TradingView
AKYA
Akoya Biosciences, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Medical - Instruments & Supplies
0.93 52WK RANGE 3.42

People Also View

COO
COO
The Cooper Companies, Inc.
$71.61
-0.13%
 ATR
ATR
AptarGroup, Inc.
$131.01
-0.83%
 ICUI
ICUI
ICU Medical, Inc.
$127.85
-1.14%
 HAE
HAE
Haemonetics Corporation
$60.48
+2.04%
 LMAT
LMAT
LeMaitre Vascular, Inc.
$117.39
+1.93%
 ATRC
ATRC
AtriCure, Inc.
$29.40
+2.58%
 ATRI
ATRI
Atrion Corporation
$459.92
+0.06%
 ANGO
ANGO
AngioDynamics, Inc.
$10.47
+2.25%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message